CSOP Hang Seng Biotech ETF (03174.HK) has shown strong performance at the start of the year, with a cumulative increase of over 10%! Its gain ranks among the top in the Hong Kong stock ETF market today.

As of 14:11 on January 7, 2026, CSOP Hang Seng Biotech ETF (03174.HK) has increased by over 10% this year. The fund closely tracks the Hang Seng Biotechnology Index and covers leading biotech companies listed in Hong Kong such as WuXi Biologics and BeiGene.

NewTimeSpace News: According to Wind data, as of 14:11 on January 7, 2026,CSOP Hang Seng Biotech ETF (03174.HK) has risen by 2.61%. It has performed strongly since the beginning of the year, with a cumulative increase of over 10%.

CSOP Hang Seng Biotech ETF (03174.HK) is a Hong Kong stock ETF managed by CSOP Asset Management, closely tracking the Hang Seng Biotechnology Index and covering leading biotech companies listed in Hong Kong such as WuXi Biologics and BeiGene.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.